MacroGenics, Inc. MGNX
3.74
(0.06)
(1.58%)
as of 25 Sep
- Market cap
- $242.1M
- P/E
- 0.0×
Follow MGNX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (32.61%) | (140.27%) | (86.95%) | (81.13%) |
+8 more TTM periods Free account |
|
| (4.94%) | (31.80%) | (28.78%) | (28.36%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(6.78%) | (71.74%) | (41.70%) | (37.64%) | |
Average Days of Receivables |
287.49 | 24.22 | 1.04 | 225.11 | |
Free Cash Flow per Share |
(1.03) | (1.13) | (1.31) | (2.61) | |
Free Cash Flow |
(65.53) | (71.68) | (82.94) | (164.76) | |
Capital Expenditures |
(1.81) | (1.72) | (1.90) | (2.29) | |
Piotroski F-Score |
1.00 | 2.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(29.48%) | (39.88%) | (33.01%) | (76.13%) | |
Accounts Receivable Turnover |
2.34 | 14.98 | 63.13 | 2.88 | |
Accounts Payable Turnover |
0.00 | 9.00 | 10.86 | 5.00 | |
Inventory Turnover |
— | 5.18 | 8.05 | 6.36 | |
Average Days of Payables |
0.00 | 31.90 | 26.48 | 69.08 | |
Days of Inventory on Hand |
— | 70.69 | 64.28 | 101.76 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
76.72% | 90.68% | 98.44% | 135.49% | |
Selling, General and Administrative Expense of Revenue |
20.08% | 24.29% | 26.19% | 51.43% | |
Share Based Compensation of Revenue |
5.92% | 7.99% | 9.56% | 20.39% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
4.37 | 0.99 | 1.09 | 2.14 | |
Depreciation/Fixed assets |
1.49 | 0.43 | 2.63 | 0.45 | |
Capex/Depreciation |
(0.51) | (0.35) | (0.34) | (0.36) | |
Revenue per Share |
2.88 | 2.48 | 2.37 | 1.78 | |
Operating CF per Share |
(1.00) | (1.10) | (1.28) | (2.57) | |
Capex per Share |
(0.03) | (0.03) | (0.03) | (0.04) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.02 | |
Net Profit Margin |
(7.97%) | (44.79%) | (49.91%) | (67.60%) |
Columns are period end dates